Polypid Stock News

Equities analysts expect PolyPid Ltd. (NASDAQ:PYPD) to announce ($0.52) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for PolyPids earnings. PolyPid posted earnings per share of ($0.41) during the same quarter last year, which suggests a negative year over year growth rate of 26.8%. The []

Sensus Healthcare (NASDAQ:SRTS) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability. Insider and Institutional Ownership 12.8% of Sensus Healthcare shares are owned by institutional investors. Comparatively, 9.6% []

Company Continues to Expect that the Last Patient Will be Enrolled in the Second Quarter of 2022, Followed by Top-Line Results Two Months Thereafter Company Continues to Expect that the Last Patient Will be Enrolled in the Second Quarter of 2022, Followed by Top-Line Results Two Months Thereafter

PolyPid (NASDAQ:PYPD) and Sensus Healthcare (NASDAQ:SRTS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk. Earnings & Valuation This table compares PolyPid and Sensus Healthcares revenue, earnings per share and valuation. []

Company is Scheduled to Conduct Pre-IND Meeting with the U.S. FDA Later This Month and Potentially Initiate Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors in 2022 Company is Scheduled to Conduct Pre-IND Meeting with the U.S. FDA Later This Month and Potentially Initiate Phase 1/2 Clinical Trial of OncoPLEX for Brain Tumors in 2022

PolyPid's (PYPD) CEO Amir Weisberg on Q3 2021 Results - Earnings Call Transcript

PETAH TIKVA, Israel, Nov. 01, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a phase 3 biopharmaceutical company focused on developing targeted, locally a

PolyPid Ltd (NASDAQ: PYPD) has announced preclinical data in two key Glioblastoma Multiform (GBM) animal models of its OncoPLEX intra-tumoral cancer therapy program. OncoPLEX is designed to provide

PETAH TIKVA, Israel, Sept. 13, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release the

PolyPid Ltd's (PYPD) CEO Amir Weisberg on Q2 2021 Results - Earnings Call Transcript

•  Recruitment Progressing as Planned with Over 3 00 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100  in Abdominal Surgery

Presentation led by PolyPid EVP & CFO is taking place today on June 23, 2021 at 9:20am EDT Presentation led by PolyPid EVP & CFO is taking place today on June 23, 2021 at 9:20am EDT

PETAH TIKVA, Israel, June 02, 2021 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extende

PolyPid Ltd (NASDAQ: PYPD) has received written responses from the FDA to a Type B meeting request that the company submitted regarding its development plan for its lead candidate, D-PLEX100. The F

PolyPid's (PYPD) CEO Amir Weisberg on Q1 2021 Results - Earnings Call Transcript